Infection rates were similar in patients treated with intravenous immunoglobulin (IVIG) whether they were dosed traditionally or with a precision-dosing strategy, according to a study involving 209 individuals. Moreover, precision-dosing was less costly. Participants received IVIG using either a traditional (n=125) or precision (n=84) dosing strategy. Investigators looked at 30- and 60-day infection rates, immunoglobulin G level response, and IVIG savings. Among the results:

• 30-day infection rate in each cohort was 16%.
• 60-day infection rates were not significantly different (23% in the traditional dosing group and 20% in the precision-dosing contingent).
• Each group experienced an 86% treatment response rate.
• Precision-dosing led to $2,600/month in institutional savings.

The authors estimated that complete adherence to a precision-dosing strategy would lead to an additional $4,600/month in savings.